Find Reports
Select Report Type
Reimbursement Review
Displaying 1351 - 1375 of 1422
Please scroll or swipe to the right to view the full content.
| Title | Brand Name | Generic Name | Files | Therapeutic Area | Recommendation Type | Status | Submission Date | Recommendation Date Sort ascending | Project Number |
|---|---|---|---|---|---|---|---|---|---|
| trastuzumab deruxtecan | Enhertu | trastuzumab deruxtecan | Gastric or gastroesophageal junction (GEJ) adenocarcinoma | Active | PC0367-000 | ||||
| quizartinib | Vanflyta | quizartinib | acute myeloid leukemia (AML) | Active | PC0359-000 | ||||
| leuprolide mesylate | Camcevi | leuprolide mesylate | Prostate cancer | Active | PC0370-000 | ||||
| durvalumab | Imfinzi | durvalumab | resectable non-small cell lung cancer (NSCLC) | Active | PC0372-000 | ||||
| isatuximab | Sarclisa | isatuximab | multiple myeloma not eligible for ASCT | Active | PC0378-000 | ||||
| belantamab mafodotin, bortezom... | TBC | belantamab mafodotin, bortezomib, dexamethasone | Previously treated multiple myeloma | Active | PC0379-000 | ||||
| belantamab mafodotin, pomalido... | TBC | belantamab mafodotin, pomalidomide, dexamethasone | Previously treated multiple myeloma | Active | PC0380-000 | ||||
| dostarlimab | Jemperli | dostarlimab | Endometrial cancer | Active | PC0381-000 | ||||
| inavolisib | Itovebi | inavolisib | Advanced or metastatic breast cancer | Active | PC0382-000 | ||||
| pembrolizumab | Keytruda | pembrolizumab | Advanced or recurrent endometrial carcinoma | Active | PC0383-000 | ||||
| daratumumab | Darzalex SC | daratumumab | Multiple myeloma, eligible for autologous stem cell transplant | Active | PC0388-000 | ||||
| durvalumab | Imfinzi | durvalumab | limited-stage small cell lung cancer (LS-SCLC) | Active | PC0389-000 | ||||
| durvalumab, tremelimumab | Imfinzi, Imjudo | durvalumab, tremelimumab | Metastatic non-small cell lung cancer (NSCLC) | Active | PC0390-000 | ||||
| pemigatinib | Pemazyre | pemigatinib | Cholangiocarcinoma | Active | PC0391-000 | ||||
| nivolumab and ipilimumab | Opdivo and Yervoy | nivolumab and ipilimumab | Unresectable or metastatic MSI-H or dMMR colorectal cancer | Active | PC0396-000 | ||||
| polatuzumab vedotin | Polivy | polatuzumab vedotin | Large B-cell lymphoma | Active | PC0397-000 | ||||
| osimertinib | Tagrisso | osimertinib | Unresectable (stage III) non-small cell lung cancer | Active | PC0398-000 | ||||
| abemaciclib | Verzenio | abemaciclib | HR-positive, HER2-negative advanced or metastatic breast cancer | Active | PC0400-000 | ||||
| lazertinib and amivantamab | Lazcluze and Rybrevant | lazertinib and amivantamab | Locally advanced or metastatic non-small cell lung cancer (NSCLC) | Active | PC0392-000 | ||||
| amivantamab | Rybrevant | amivantamab | Locally advanced or metastatic non-small cell lung cancer (NSCLC) | Active | PC0393-000 | ||||
| mirvetuximab soravtansine | TBC | mirvetuximab soravtansine | Epithelial ovarian, fallopian tube, or primary peritoneal cancer | Active | PC0394-000 | ||||
| ribociclib | Kisqali | ribociclib | Adjuvant treatment of HR-positive, HER2-negative early breast cancer | Active | PC0395-000 | ||||
| venetoclax | Venclexta | venetoclax | Mantle cell lymphoma (MCL) | Active | PC0402-00 | ||||
| asciminib | Scemblix | asciminib | Philadelphia chromosome-positive chronic myeloid leukemia | Active | PC0405-000 | ||||
| glofitamab | Columvi | glofitamab | Relapsed or refractory diffuse large B-cell lymphoma | Active | PC0406-000 |
Health Technology Review
Displaying 576 - 600 of 600
Horizon Scan
Displaying 101 - 110 of 110
Projects in Progress
Displaying 26 - 27 of 27
View All Reports
Displaying 1351 - 1375 of 2132
Please scroll or swipe to the right to view the full content.
| Title | Description | Files | Last Updated Sort ascending | Project Line | Project Sub Line | Status | Project Number |
|---|---|---|---|---|---|---|---|
| CADTH Pharmaceutical Reviews Update — Issue 11 | Reimbursement Review | Pharmaceutical Review Update | |||||
| Biopsy for Adults with Suspected Skin Cancer: A Rapid Qualitative Review | Health Technology Review | Rapid Review | Completed | RC1215-000 | |||
| Dosing and Timing of Immuno-Oncology Drugs | Health Technology Review | Technology Review | Completed | HO0008-000 | |||
| Larotrectinib for Neurotrophic Tyrosine Receptor Kinase (NTRK) Locally Advanced or Metastatic Solid Tumours – Details | Reimbursement Review | Complete | PC0159-000 | ||||
| Idhifa for Acute Myeloid Leukemia – Details | Reimbursement Review | Complete | PC0144-000 | ||||
| Prostatectomy for People with Prostate Cancer: A Rapid Qualitative Review | Health Technology Review | Summary with Critical Appraisal | Completed | RC1209-000 | |||
| Genome-Wide Sequencing: Ethical Considerations | Health Technology Review | Technology Review | Completed | HE0020-000 | |||
| Health Technology Update - Issue 25 | Horizon Scan | Completed | EN0015-000 | ||||
| benralizumab | Reimbursement Review | Complete | SF0592-000 | ||||
| mepolizumab | Reimbursement Review | Complete | SF0593-000 | ||||
| ulipristal acetate | Reimbursement Review | Complete | SF0609-000 | ||||
| reslizumab | Reimbursement Review | Complete | SF0591-000 | ||||
| ulipristal acetate | Reimbursement Review | Complete | SF0528-000 | ||||
| pegfilgrastim | Reimbursement Review | Complete | SE0588-000 | ||||
| Pegfilgrastim | Reimbursement Review | Complete | SE0555-000 | ||||
| infliximab | Reimbursement Review | Complete | SE0532-000 | ||||
| lurasidone | Reimbursement Review | Not filed | NS0010-000 | ||||
| Healthy Aging | Health Technology Review | ES0342-000 | |||||
| Screening and Diagnostic Services for People at Risk of Breast Cancer: A Rapid Qualitative Review | Health Technology Review | Rapid Review | Completed | RC1208-000 | |||
| nitisinone | Reimbursement Review | Complete | SR0531-000 | ||||
| doravirine | Reimbursement Review | Complete | SR0582-000 | ||||
| risankizumab | Reimbursement Review | Complete | SR0583-000 | ||||
| Nelarabine for Acute Lymphoblastic Leukemia - Details | Reimbursement Review | Cancelled | PC0170-000 | ||||
| Dementia Villages | Horizon Scan | Emerging Health Technologies | Completed | EH0071-000 | |||
| Dementia Villages - Position Statement | Horizon Scan | EH0071-000 |